#United States #Philadelphia #Integral Molecular #Paratope-PLUS™ #GPRC5D

Integral Molecular's Significant Patent Advancement

In a groundbreaking achievement, Integral Molecular has announced that the United States Patent and Trademark Office (USPTO) has approved a patent pertaining to a genus of antibodies. This innovation is made possible through the application of their proprietary Paratope-PLUS™ CDR-Scanning technology. This technology enables the firm to secure a patent that encompasses a lead candidate and a spectrum of structurally related antibodies that effectively bind to GPRC5D, a target known for its cancer relevance.

The importance of this patent cannot be overstated, as it illustrates a new conduit for safeguarding antibody genera, supported by robust experimental data. This development aligns with the guidelines set forth by the 2023 U.S. Supreme Court ruling on Amgen Inc. v. Sanofi, which had reinforced that genus claims must have sufficient disclosure compliant with 35 U.S.C. §112 for enablement and written description. Integral Molecular's approach effectively meets these stipulations by defining a shared structural characteristic of the genus, specifically the paratope responsible for target binding.

Utilizing Advanced Technology for Robust Data Generation

Integral Molecular has leveraged its Paratope-PLUS platform to create extensive datasets that support these genus claims. This platform employs a systematic mutation process for the antibody's Complementarity Determining Regions (CDRs). By altering each residue of the CDRs to explore all 19 alternative amino acids, the firm has meticulously identified variants that not only retain key functions but often enhance them.

The CDR-Scanning technology takes a methodological approach reminiscent of small molecule claims, where core structural features are claimed alongside all permissible variants surrounding them. This methodically generates a genus of antibodies characterized by specific mutations, including both individual changes and complex combinations. This provides a comprehensive understanding of permissible levels of binding, thus ensuring robust patent claims.

A Perspective on the Future of Antibody Patent Protection

In an interview regarding this pivotal advancement, Benjamin Doranz, CEO of Integral Molecular, emphasized the transformative role of big data in antibody drug development and patent protection. He noted that with the increasing capabilities of high-throughput technologies, the creation of a comprehensive data package—aligned with USPTO guidelines—has become both feasible and scalable. This strategy is critical to establishing solid intellectual property (IP) protection for antibody innovations.

Integral Molecular's Paratope-PLUS program promises to deliver not only laboratory-generated expression and binding data for every antibody variant but also a framework for a genus of structurally related antibodies. This generation meets the crucial requirements for patent enablement and written description, leading to broader patent claims for the company.

The forthcoming discussions by CEO Benjamin Doranz at the Life Sciences Patent Network conference, scheduled for April 29, 2026, will likely illuminate the application of CDR-Scanning technology in enhancing antibody intellectual property. He has recently elaborated on this strategy in a webinar titled “Resurrecting Antibody Genus Protection,” hosted by IP Watchdog.

Conclusion

Integral Molecular's achievement with the USPTO underscores a significant moment in the field of biotechnology, particularly for antibody patenting strategies. With innovations such as Paratope-PLUS™, the company is set to lead the way in redefining protective measures for antibody therapeutics, paving the way for the advancement of novel treatments against challenging health threats. Given their long-standing expertise of over 25 years focused on membrane proteins, viruses, and antibodies, Integral Molecular continues to play a pivotal role in the ongoing quest to develop new therapies combatting cancer, autoimmune disorders, and infectious diseases.